According to the settlement agreement, Genevant Sciences, a subsidiary of Roivant Sciences Ltd., will grant Moderna, Inc. a non-exclusive license allowing the use of its lipid nanoparticle delivery technology for applications in the field of infectious diseases.
Show original
This arrangement resolves the intellectual property dispute between both parties.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
NEAR co-founder: AI agents will become the main users of blockchain
PANews•2026/03/04 01:09
U.S. stocks closed with most crypto-related sectors down, UPXI fell more than 10.78%
AIcoin•2026/03/04 01:03
Bridgewater founder Dalio: Bitcoin is not suitable as digital gold
AIcoin•2026/03/04 00:59
Trending news
MoreCrypto prices
MoreBitcoin
BTC
$68,185.59
-1.20%
Ethereum
ETH
$1,979.21
-2.60%
Tether USDt
USDT
$1
+0.03%
BNB
BNB
$632.44
-1.15%
XRP
XRP
$1.36
-2.07%
USDC
USDC
$1
+0.02%
Solana
SOL
$86.71
-0.11%
TRON
TRX
$0.2792
-1.47%
Dogecoin
DOGE
$0.08985
-3.83%
Cardano
ADA
$0.2628
-4.66%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now